search
Back to results

Cardiac Involvement in Wilson's Disease (WIL-HEART)

Primary Purpose

Wilson's Disease

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope
Sponsored by
Fondation Ophtalmologique Adolphe de Rothschild
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Wilson's Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patient with Wilson's disease confirmed by a Leipzig score ≥ 4
  • Express consent to participate in the study by the patient or legal guardian in the case of patients under guardianship or by the patient assisted by his curator in the case of patients under guardianship
  • Member of or beneficiary of a Social Security scheme

Exclusion Criteria:

  • Absolute or relative contraindication to MRI or contrast media
  • Pregnant, parturient or breast-feeding women: a urine pregnancy test will be carried out in women of childbearing age
  • Patient with hepatic decompensation (Child-Pugh score stage C)
  • Patient in neuro-psychiatric decompensation

Sites / Locations

  • Fondation Adolphe de RothschildRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Cases

Arm Description

The intervention consists in setting up a morphological and rhythmological cardiological follow-up patients with confirmed Wilson disease. It will require the wearing of a long Holter duration (21 days) and for some patients the installation of an implantable cardiac monitor.The long-time ECG holter is used to record heart rhythm for 21 days and detect possible arrhythmias (accelerations of the heart) or conduction disorders (slowdowns of the heart).

Outcomes

Primary Outcome Measures

Contrast-enhanced cardiac MRI - Day 0
Percentage of patients with abnormal contrast-enhanced cardiac MRI results
Contrast-enhanced cardiac MRI - Day 0
Description of abnormalities (frequency and percentage)
Transthoracic echocardiography - Day 0
Percentage of patients with abnormal transthoracic echocardiography results
Transthoracic echocardiography - Day 0
Description of abnormalities (frequency and percentage)
Chest computed tomography scan without contrast - Day 0
Percentage of patients with abnormal coronary artery calcium score Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.
Electrocardiogram - Day 0
Percentage of patients with abnormal electrocardiogram results
Electrocardiogram - Day 0
Description of abnormalities (frequency and percentage)
Clinical examination - Day 0
Percentage of patients with abnormal clinical examination
Clinical examination - Day 0
Description of abnormalities (frequency and percentage)
Blood and urine tests - Day 0
Percentage of patients with abnormal blood and urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Blood and urine tests - Day 0
Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Lying and standing blood pressure tests - Day 0
Percentage of patients with abnormal blood pressure tests results
Lying and standing blood pressure tests - Day 0
Description of abnormalities (frequency and percentage)
Implantable loop recorder or ECG holter recorder- Day 21
Percentage of patients with abnormal implantable loop record (or ECG holter record) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.
Implantable loop recorder or ECG holter recorder- Day 21
Description of abnormalities (frequency and percentage) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.
Transthoracic echocardiography - Year 3
Percentage of patients with abnormal transthoracic echocardiography results
Transthoracic echocardiography - Year 3
Description of abnormalities (frequency and percentage)
Contrast-enhanced cardiac MRI - Year 3
Percentage of patients with abnormal contrast-enhanced cardiac MRI results
Contrast-enhanced cardiac MRI - Year 3
Description of abnormalities (frequency and percentage)
Chest computed tomography scan without contrast - Year 3
Percentage of patients with abnormal coronary artery calcium score Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.
Electrocardiogram - Year 3
Percentage of patients with abnormal electrocardiogram results
Electrocardiogram - Year 3
Description of abnormalities (frequency and percentage)
Clinical examination - Year 3
Percentage of patients with abnormal clinical examination
Clinical examination - Year 3
Description of abnormalities (frequency and percentage)
Blood and urine tests - Year 3
Percentage of patients with abnormal blood or urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Blood and urine tests - Year 3
Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Lying and standing blood pressure tests - Year 3
Percentage of patients with abnormal blood pressure tests results
Lying and standing blood pressure tests - Year 3
Description of abnormalities (frequency and percentage)

Secondary Outcome Measures

Full Information

First Posted
July 21, 2022
Last Updated
May 10, 2023
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
search

1. Study Identification

Unique Protocol Identification Number
NCT05493605
Brief Title
Cardiac Involvement in Wilson's Disease
Acronym
WIL-HEART
Official Title
Cardiac Involvement in Wilson's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 2, 2023 (Actual)
Primary Completion Date
March 2026 (Anticipated)
Study Completion Date
March 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondation Ophtalmologique Adolphe de Rothschild

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. This could suggest that the clinical manifestations related to the copper accumulation in the heart appears with the duration of the disease. Case-control studies on adult populations have highlighted various electrocardiographic (ECG) abnormalities more frequent in patients with Wilson's Disease than in healthy volunteers, but all these studies involved small number of patients (maximum 60). The hypothesis is that there is cardiac involvement in Wilson's Disease, requiring screening, follow-up and appropriate support.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wilson's Disease

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
All patients with confirmed Wilson Disease presenting for consultation or hospitalization for their follow-up or at the time of diagnosis will be offered to participate in the study. Patients who have already benefited from a cardiac assessment with installation of an implantable Holter ECG as part of the treatment may be included retrospectively
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cases
Arm Type
Other
Arm Description
The intervention consists in setting up a morphological and rhythmological cardiological follow-up patients with confirmed Wilson disease. It will require the wearing of a long Holter duration (21 days) and for some patients the installation of an implantable cardiac monitor.The long-time ECG holter is used to record heart rhythm for 21 days and detect possible arrhythmias (accelerations of the heart) or conduction disorders (slowdowns of the heart).
Intervention Type
Procedure
Intervention Name(s)
Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope
Intervention Description
The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
Primary Outcome Measure Information:
Title
Contrast-enhanced cardiac MRI - Day 0
Description
Percentage of patients with abnormal contrast-enhanced cardiac MRI results
Time Frame
Day 0
Title
Contrast-enhanced cardiac MRI - Day 0
Description
Description of abnormalities (frequency and percentage)
Time Frame
Day 0
Title
Transthoracic echocardiography - Day 0
Description
Percentage of patients with abnormal transthoracic echocardiography results
Time Frame
Day 0
Title
Transthoracic echocardiography - Day 0
Description
Description of abnormalities (frequency and percentage)
Time Frame
Day 0
Title
Chest computed tomography scan without contrast - Day 0
Description
Percentage of patients with abnormal coronary artery calcium score Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.
Time Frame
Day 0
Title
Electrocardiogram - Day 0
Description
Percentage of patients with abnormal electrocardiogram results
Time Frame
Day 0
Title
Electrocardiogram - Day 0
Description
Description of abnormalities (frequency and percentage)
Time Frame
Day 0
Title
Clinical examination - Day 0
Description
Percentage of patients with abnormal clinical examination
Time Frame
Day 0
Title
Clinical examination - Day 0
Description
Description of abnormalities (frequency and percentage)
Time Frame
Day 0
Title
Blood and urine tests - Day 0
Description
Percentage of patients with abnormal blood and urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Time Frame
Day 0
Title
Blood and urine tests - Day 0
Description
Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Time Frame
Day 0
Title
Lying and standing blood pressure tests - Day 0
Description
Percentage of patients with abnormal blood pressure tests results
Time Frame
Day 0
Title
Lying and standing blood pressure tests - Day 0
Description
Description of abnormalities (frequency and percentage)
Time Frame
Day 0
Title
Implantable loop recorder or ECG holter recorder- Day 21
Description
Percentage of patients with abnormal implantable loop record (or ECG holter record) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.
Time Frame
Day 21
Title
Implantable loop recorder or ECG holter recorder- Day 21
Description
Description of abnormalities (frequency and percentage) The device will record from Day 0 to Day 21 Implantable loop recorder assessment will be only performed on patients with syncope.
Time Frame
Day 21
Title
Transthoracic echocardiography - Year 3
Description
Percentage of patients with abnormal transthoracic echocardiography results
Time Frame
Year 3
Title
Transthoracic echocardiography - Year 3
Description
Description of abnormalities (frequency and percentage)
Time Frame
Year 3
Title
Contrast-enhanced cardiac MRI - Year 3
Description
Percentage of patients with abnormal contrast-enhanced cardiac MRI results
Time Frame
Year 3
Title
Contrast-enhanced cardiac MRI - Year 3
Description
Description of abnormalities (frequency and percentage)
Time Frame
Year 3
Title
Chest computed tomography scan without contrast - Year 3
Description
Percentage of patients with abnormal coronary artery calcium score Calcium score : The higher the coronary calcium score, the greater the cardiovascular risk. A score of 0 (min) means that no calcium is seen in the heart. A score greater than 300 is a sign of very high to severe disease.
Time Frame
Year 3
Title
Electrocardiogram - Year 3
Description
Percentage of patients with abnormal electrocardiogram results
Time Frame
Year 3
Title
Electrocardiogram - Year 3
Description
Description of abnormalities (frequency and percentage)
Time Frame
Year 3
Title
Clinical examination - Year 3
Description
Percentage of patients with abnormal clinical examination
Time Frame
Year 3
Title
Clinical examination - Year 3
Description
Description of abnormalities (frequency and percentage)
Time Frame
Year 3
Title
Blood and urine tests - Year 3
Description
Percentage of patients with abnormal blood or urine tests results Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Time Frame
Year 3
Title
Blood and urine tests - Year 3
Description
Description of abnormalities (frequency and percentage) Blood tests performed : lipid profile, glycosylated hemoglobin (HbA1C), cardiac enzymes (troponin C, NT-proBNP), ultra-sensitive C-reactive protein, sodium level, potassium level, urea and creatinine clearance, TSH, fibrinogen Urine test performed : proteinuria
Time Frame
Year 3
Title
Lying and standing blood pressure tests - Year 3
Description
Percentage of patients with abnormal blood pressure tests results
Time Frame
Year 3
Title
Lying and standing blood pressure tests - Year 3
Description
Description of abnormalities (frequency and percentage)
Time Frame
Year 3

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patient with Wilson's disease confirmed by a Leipzig score ≥ 4 Express consent to participate in the study by the patient or legal guardian in the case of patients under guardianship or by the patient assisted by his curator in the case of patients under guardianship Member of or beneficiary of a Social Security scheme Exclusion Criteria: Absolute or relative contraindication to MRI or contrast media Pregnant, parturient or breast-feeding women: a urine pregnancy test will be carried out in women of childbearing age Patient with hepatic decompensation (Child-Pugh score stage C) Patient in neuro-psychiatric decompensation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Amélie YAVCHITZ
Phone
01 48 03 64 54
Email
ayavhitz@for.paris
First Name & Middle Initial & Last Name or Official Title & Degree
Aurélia POUJOIS
Phone
01 48 30 66 56
Email
apoujois@for.paris
Facility Information:
Facility Name
Fondation Adolphe de Rothschild
City
Paris
ZIP/Postal Code
75019
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aurélia Poujois
Phone
0148036656
Email
apoujois@for.paris

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Cardiac Involvement in Wilson's Disease

We'll reach out to this number within 24 hrs